Dermira reports new data in pediatric patients with axillary hyperhidrosis
Dermira reported findings from its glycopyrronium tosylate Phase 3 clinical program. The data showed when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediatric patients. February 17, 2018